Close

We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
For more information, go to www.arthritisresearchuk.org

Previous successful proposals

To date, four studies have been funded as a consequence of applications to the Inflammatory Arthritis CSG. The funded studies are:

  • ORBIT: Optimal treatment of RA patients requiring Biologic therapy.
    Duncan Porter and colleagues. A head-to-head comparison of rituximab and anti-TNF as first biologic therapy. This trial includes a pilot sub-study: Optimising the therapeutic utility of biologic agents using a synovial pathotype (OPUS), from the “Pathobiology of Early Arthritis Cohort” (PEAC). (Pitzalis, McInnes et al). This study asks whether a baseline synovial biopsy can inform the optimal therapeutic algorithm for an individual patient commencing biologic therapy.
  • Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A Proof Of Principle And Exploratory Trial. Prof DL Scott. This study addresses whether it is possible to taper therapy in the established RA patient who is in remission on anti-TNF therapy.
  • Development of the Rheumatoid Arthritis Patient Priorities for Pharmacological Interventions (RAPP-PI) outcome measures. (Pilot study, PI Dr T Sanderson, University of the West of England).
  • Work Rehabilitation in Inflammatory Arthritis. Effectiveness and cost effectiveness of an occupational therapy (OT) job retention intervention: a randomised controlled trial. (Pilot study, PI Dr A Hammond, Salford University).

  

 

For more information, go to www.arthritisresearchuk.org.
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.